Lipocine (NASDAQ:LPCN) Earns Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Monday. The firm set a “buy” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Down 4.8 %

Lipocine stock opened at $3.76 on Monday. The stock has a fifty day moving average price of $4.57 and a 200 day moving average price of $5.13. Lipocine has a 52 week low of $3.30 and a 52 week high of $10.33. The firm has a market capitalization of $19.99 million, a P/E ratio of -1.58 and a beta of 0.96.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.04). As a group, equities analysts predict that Lipocine will post -2.7 EPS for the current year.

Hedge Funds Weigh In On Lipocine

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in shares of Lipocine in the 2nd quarter worth $160,000. Renaissance Technologies LLC grew its holdings in shares of Lipocine by 146.2% during the 3rd quarter. Renaissance Technologies LLC now owns 199,400 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 118,394 shares during the period. Goldman Sachs Group Inc. increased its position in Lipocine by 524.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 74,428 shares in the last quarter. Wealthspan Partners LLC purchased a new position in Lipocine in the fourth quarter valued at approximately $29,000. Finally, EP Wealth Advisors LLC purchased a new position in Lipocine in the first quarter valued at approximately $13,395,000. Institutional investors and hedge funds own 8.99% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.